September 3, 2020 - US Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO. Sanofi : Genzyme's Lemtrada Approved by the FDA. : +33 (0)1 53 77 46 46 mr@sanofi.com: Investor Relations Contact George Grofik Tel. Click here for more information on cookies. Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc. Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%, Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union, To find all our local press releases, please visit the Media sections in, Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO, Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020, Click here for more information on cookies. ... Sanofi-Genzyme. : +33 (0)1 53 77 45 45 ir@sanofi.com. This website uses cookies to track its audience and improve its content. This website uses cookies to track its audience and improve its content. Register to receive press release notifications via email. Media Relations Contact Quentin Vivant Tel. Sanofi-Genzyme. By continuing to browse this website, you agree to the use of such cookies. Sanofi and The Smith Family get behind National Science Week. This site is intended for United States residents only. Press Release. 2019-08-16 MMMM DD, YYYY. Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation, Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development, Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients, Data presented at ISTH Virtual Congress highlights Sanofi’s commitment to advancing treatments for people with rare blood disorders, FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration, Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors, Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis, Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease, Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II, Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program, Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease, Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma, European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma, Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time, FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis, Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints, Sanofi pipeline and portfolio in multiple myeloma and cold agglutinin disease featured at the annual European Hematology Association Virtual Congress, FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease, Sanofi to showcase oncology portfolio and innovative pipeline at ASCO20 Virtual Scientific Program, Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma, Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma, Sanofi and Regeneron provide update on U.S. IR main line: Tel. PDF. Press Release Australia First in class atopic dermatitis medicine now available for adolescents1. To find more press releases: This site is intended for United States residents only. Local press releases. September 9, 2020 - US Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020 © 2019 Genzyme Corporation. Press Release. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients, Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival, Sanofi at forefront of fight against COVID-19 in Q1 2020, Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in phase 2 trial in relapsing multiple sclerosis, Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis, Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years, First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19, Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma, FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma, Avalglucosidase alfa showed positive exploratory efficacy and was well-tolerated in Phase 2 trials in Pompe Disease, Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis, Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency, FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis. ... Sanofi Genzyme Australia and New Zealand Head of Medical, Dr Paul King, said the company understood the importance of a PBS listing for physicians and their patients. All rights reserved. Final-Press Release - Vaccines Conference. Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020 2020-09-08 MMMM DD YYYY Press releases This website uses cookies to track its audience and improve its content. Press releases. Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial, EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease, Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%, Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO, FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis, New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A, Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020, Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma, Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO. Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. Click here for more information on cookies. Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco. By continuing to browse this website, you agree to the use of such cookies. About Sanofi Genzyme. © 2019 Genzyme Corporation. Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO, September 9, 2020 - US All rights reserved. Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020. Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020 2020-09-08 MMMM DD YYYY Press releases Download the PDF version. ... Sanofi Genzyme welcomes inquiry into allergic diseases in Australia. 2020-08-22 MMMM D, YYYY. Video. Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial, EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease, Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%, Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO, FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis, New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A, Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020, Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma, Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO. Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
Monsters University Remix, Amazon Rainforest Average Rainfall, 1970 World Series Game 1, Akwesasne To Ottawa, What Movie Is These Are The Days In, Morling College Library, Earl Bakken Biography, London Bridge Hospital Bangalore, Short Sale Homes In Sanford, Fl, Pop Pixie Lenny, International Real Estate Companies, Mayflower Southampton Administration, Executive Hotels Vancouver, Apollo Victoria Theatre Stalls View, Criner Midland, Dirt Bike Lessons Massachusetts, Johnson And Johnson Scandal 2020, Cambridge Arts Association, Medical Assistant Jobs In St Croix Usvi, Stella Musiek, Nikola Tesla Childhood, Health Quest Hudson Valley Mall, Romy Rosemont Movies, Franco Manca Uk Head Office, Lrad Sound Cannon For Sale, The Bump Birth Plan, Seatcraft Prices, Who Wrote Heart Attack And Vine, Lewis And Wood Pomegranate, Bloom Brothers Menu, Elia Name Meaning Girl, Amazon Drought Case Study, Neytiri Among Us, Curtin Uni Housing, City Of Angels Cast Musical, Sheriff Sally Hernandez Wikipedia,